Back

Samsung Biologics to spend 2.7 trillion won on PolyPeptide acquisition

Verifying
  • Samsung Biologics plans to acquire PolyPeptide Group and enter peptide manufacturing.
  • The company will allocate 2.7062 trillion won of its rights offering to the acquisition.
  • Samsung Biologics plans 15.4 trillion won of investments through 2034.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.